Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is representing Bora Pharmaceuticals in its acquisition of Upsher-Smith Laboratories. Bora Pharmaceuticals Co., Ltd. announced the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised United Therapeutics Corporation on its acquisition of Miromatrix Medical Inc., assisted by Faegre Drinker Biddle & Reath LLP. Piper Sandler...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer advised Indivumed GmbH on the deal while Sidley is represented Crown Bioscience. Indivumed GmbH sold its “IndivuServ” business unit to a wholly owned...
You must be a Standard 1 Year member to access this content.
Sidley Austin advised the underwriters on the deal, while Choate and Latham & Watkins assisted Immuneering Corporation. Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
You must be a Standard 1 Year member to access this content.
